Status:
ENROLLING_BY_INVITATION
EGPSS for Weight Management in an in Vivo Human Model
Lead Sponsor:
Liu Yan
Conditions:
Obesity, Mild
Eligibility:
All Genders
18-70 years
Phase:
NA
Brief Summary
ndoscopic bariatric and metabolic therapies (EBMTs) have introduced more convenient, minimally invasive, and safe approaches to weight management. Mucosal ablation of the gastric fundus has been repor...
Detailed Description
The global prevalence of obesity has increased over the past five decades. Endoscopic bariatric and metabolic therapies (EBMTs) have introduced more convenient, minimally invasive, and safe approaches...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Patients with a body mass index (BMI) of 24-35 kg / m²;
- Patients accepted Lifestyle modifications, pharmacological interventions for weight loss which were unsuccessful or experienced a weight rebound;
- Patients willing to loss weight;
- Obese patients with metabolic disorders.
- Exclusion criteria:
- Women who are planning to conceive, pregnant, or breastfeeding;
- Patients who are suffering from severe organ failure requiring hospitalization;
- Patients who have undergone gastrectomy;
- Patients allergic to anesthetics.
Exclusion
Key Trial Info
Start Date :
July 1 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2025
Estimated Enrollment :
15 Patients enrolled
Trial Details
Trial ID
NCT07186959
Start Date
July 1 2024
End Date
December 31 2025
Last Update
September 22 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The fifth Medical Center of Chinese PLA General Hospital
Beijing, Beijing Municipality, China, 100071